ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+

 
• By Malcolm Spicer

A week after announcing 2024 full-year and fourth-quarter results, the firm says its corporate name will be Niagen Bioscience Inc. starting 19 March. It stated in its latest results that during 2024 it launched Niagen Plus line of pharmaceutical-grade Niagen.

ChromaDex rolled out Rx nicotinamide adenine dinucleotide products in August, along with a test kit for providers and consumers. (Source: CHromaDex)

More from Strategy

More from HBW Insight